Philip Rawlins

Philip Rawlins

Philip Rawlins has extensive drug discovery experience across a broad range of target classes and assay formats with over 20 years working in the industry. Having previously worked at AstraZeneca, he is now Group Leader at Domainex, specialising in assay biology and biophysics in particular.

  • G-protein-coupled,Receptors,(gpcrs),From,Left,To,Right,,Rhodopsin,,T-cell,Receptor
    Article

    Advancements in hit identification for membrane protein drug discovery

    2025-04-07T09:00:00

    GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.